NICE have just sent an alert with some good news about the NOACS - non-vitamin K anticoagulants such as rivaroxaban. A review has shown them to reduce the risk of fatal bleeding by about half when compared with warfarin.
The review only looked at patients with atrial fibrillation and venous thrombosis - APS is an acquired venous thrombosis - but it's a good start for the warfarin replacements.
We are still waiting to let you know about the results of the London Rivaroxaban in APS trial - but it will be soon! Again, this trial could only look at people with venous clots - DVTS - so anyone who has had a stroke or TIA will have to wait a while longer - sorry, not enough funding as usual